{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F251ff8fb-a939-467a-8b51-181b8b341853","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer \u2014 Part 3 of a Special 3-Part Edition\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/251ff8fb-a939-467a-8b51-181b8b341853\"></iframe>","title":"Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer \u2014 Part 3 of a Special 3-Part Edition","description":"\n        <p>Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice.</p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/3GU\" rel=\"nofollow\">here</a>. </p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/c7999dd6-7545-4c2e-a1fb-ac4fd9abaae8/cover.jpg"}